Inter‐fraction dose and LET robustness in LET‐optimized proton therapy for pediatric, adolescent and young adult intracranial tumors
Medical Physics · 2026
DOI: 10.1002/mp.70214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Physics, 2026. Verfasst von Alfredo Mirandola und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Physics Unit, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy. Hauptthemen laut MEDLINE: Proton Therapy, Brain Neoplasms, Linear Energy Transfer, Dose Fractionation, Radiation. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Although pediatric, adolescent and young adults (AYA) patients are known to be eligible for proton therapy, the presence of high linear energy transfer (LET) in critical structures, such as the brainstem, could lead to an increased risk of toxicity. To address this issue, dose‐averaged LET (LET d )‐optimized (LO) planning strategies have been proposed as a means to mitigate LET‐related risks while maintaining dose quality. However, the balance between dose distribution quality, LET d optimization, and plan robustness must be evaluated across the entire treatment course. As the treatments here investigated are delivered in multiple fractions, the assessment of the benefits of LET d optimization and its robustness against the anatomical and setup variations during treatment course, is crucial.
Purpose
This study investigates the inter‐fraction robustness of LO plans compared to standard (STD) dose‐driven plans in pediatric and AYA patients with intracranial tumors. Both dose and LET d distributions were evaluated using re‐evaluation CTs acquired during treatment. Additionally, recalculations with variable relative biological effectiveness (RBE) models were performed to investigate plan sensitivity to biological uncertainties.
Methods
Twenty patients (prescription dose ≥ 54 Gy) were retrospectively included. For each patient, STD and LO plans were generated and clinically approved by a medical doctor. Both plan types were optimized with robust optimization parameters, including 2 mm setup and 3.5% range uncertainties. Reference plans were subsequently recalculated using variable RBE models, in addition to the fixed RBE = 1.1 assumption. To evaluate robustness, all plans were recalculated on re‐evaluation CTs acquired throughout the treatment course. Dosimetric endpoints included D 98% and D 1% for the clinical target volume (CTV) and D 1% for the brainstem. LET d robustness was assessed by quantifying the brainstem volume receiving > 50 Gy and LET d above thresholds of 4, 3.5, and 3 keV/µm (V50@LET d x).
Results
LO and STD plans exhibited comparable dose distributions, with no statistically significant differences in CTV coverage or brainstem sparing. In terms of LET, LO plans achieved a significant reduction in V50@LET d x volumes ( p < 0.01). Furthermore, inter‐fraction variation in LET d ‐sensitive brainstem volumes was lower in LO plans, indicating enhanced LET d robustness across the treatment course. As expected, due to the optimized LET d values in the brainstem, plan recalculations with variable RBE models showed a smaller D 1% deviation in LO compared to STD plans when referenced to the fixed RBE = 1.1 model. These results demonstrate that LO not only maintains conventional dose robustness but also reduces LET d ‐related uncertainties.
Conclusions
LO and STD plans exhibited comparable dose distributions, with no statistically significant differences in CTV coverage/brainstem sparing. LO plans achieved a significant reduction in V50@LET d x ( p < 0.01). Furthermore, inter‐fraction variation in LET d for brainstem was lower in LO plans, indicating enhanced LET d robustness throughout the treatment course. The plan recalculations with variable models showed a minor D 1% deviation in LO versus STD plans, when compared to fixed 1.1 RBE model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Physics Unit, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy.
- Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
- University School for Advanced Studies of Pavia, Pavia, Italy.
- Department of Radiotherapy, IRCSS Policlinico San Donato, Milan, Italy.
- Radiation Oncology Unit, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy.
- Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.
Zitieren
APA
Mirandola, A., Bagnalasta, M., Magro, G., Bazani, A., Molinelli, S., Pavanello, V., Rossi, E., Russo, S., Trombetta, L., Vai, A., Colombo, F., Orlandi, E., Ciocca, M., & Vennarini, S. (2026). Inter‐fraction dose and LET robustness in LET‐optimized proton therapy for pediatric, adolescent and young adult intracranial tumors. Medical Physics. https://doi.org/10.1002/mp.70214
Vancouver
Mirandola A, Bagnalasta M, Magro G, Bazani A, Molinelli S, Pavanello V, et al. Inter‐fraction dose and LET robustness in LET‐optimized proton therapy for pediatric, adolescent and young adult intracranial tumors. Medical Physics. 2026. doi:10.1002/mp.70214
BibTeX
@article{Mirandola2026,
author = {Mirandola, Alfredo and Bagnalasta, Matteo and Magro, Giuseppe and Bazani, Alessia and Molinelli, Silvia and Pavanello, Vittoria and Rossi, Eleonora and Russo, Stefania and Trombetta, Luca and Vai, Alessandro and Colombo, Francesca and Orlandi, Ester and Ciocca, Mario and Vennarini, Sabina},
title = {Inter‐fraction dose and LET robustness in LET‐optimized proton therapy for pediatric, adolescent and young adult intracranial tumors},
journal = {Medical Physics},
year = {2026},
doi = {10.1002/mp.70214}
}
EUVIMED